Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CLGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.56
1 Year Target Price $11.56
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.5% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.22M USD | Price to earnings Ratio - | 1Y Target Price 11.56 |
Price to earnings Ratio - | 1Y Target Price 11.56 | ||
Volume (30-day avg) 1 | Beta 0.78 | 52 Weeks Range 1.31 - 5.45 | Updated Date 08/28/2025 |
52 Weeks Range 1.31 - 5.45 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-20 | When - | Estimate -0.14 | Actual 0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -1775.42% |
Management Effectiveness
Return on Assets (TTM) -37.9% | Return on Equity (TTM) -78.25% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 28596600 | Price to Sales(TTM) 14.66 |
Enterprise Value 28596600 | Price to Sales(TTM) 14.66 | ||
Enterprise Value to Revenue 9.26 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 12716000 | Shares Floating 8913163 |
Shares Outstanding 12716000 | Shares Floating 8913163 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2003 in Israel. It focuses on regenerative and aesthetic medicine, developing recombinant human collagen (rhCollagen) based products.
Core Business Areas
- Regenerative Medicine: Development of rhCollagen-based products for tissue repair, wound healing, and orthopedic applications. This includes products such as Vergenix STR for tendon repair and BioBridge for spinal fusions.
- Aesthetic Medicine: Development of rhCollagen-based products for aesthetic procedures like dermal fillers. Collplant also has partnerships to explore this sector, focusing on next-generation dermal and soft tissue fillers.
- Bioprinting: Leveraging rhCollagen for 3D bioprinting of tissues and organs. This involves creating functional human tissues for research and potential transplantation.
Leadership and Structure
Yehiel Tal is the Chief Executive Officer. The company has a board of directors that oversees its operations. Collplant operates primarily in Israel with a growing global presence through partnerships.
Top Products and Market Share
Key Offerings
- Vergenix STR: A rhCollagen-based product for the treatment of tendinopathy. Market share data is not readily available as the market is relatively niche and developing. Competitors include companies offering traditional surgical options, PRP injections, and other biologic therapies.
- BioBridge: A rhCollagen-based product used in spinal fusion procedures to promote bone regeneration. This is still in development. Competitors include Medtronic (MDT), Stryker (SYK), and Johnson & Johnson (JNJ), which offer bone graft materials and spinal implants.
- rhCollagen-based dermal fillers: Collplant focuses on dermal fillers. This product is in development. Competitors include Allergan (ABBV), Galderma, and Merz Pharma.
Market Dynamics
Industry Overview
The regenerative medicine and aesthetic medicine industries are experiencing significant growth, driven by an aging population and increasing demand for minimally invasive procedures. The bioprinting market is emerging with potential for significant long-term impact.
Positioning
Collplant is positioned as an innovator in the rhCollagen space, leveraging its proprietary technology to develop unique regenerative medicine products and offering an alternative to traditional collagen sources, which are often animal-derived. They compete via strong clinical evidence and strategic partnerships.
Total Addressable Market (TAM)
The global regenerative medicine market is projected to reach hundreds of billions USD. The aesthetic medicine market is similarly large and growing. Collplant is positioned to capture a segment of this TAM via its rhCollagen technology, particularly in niche applications where its unique properties offer an advantage.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Potential for improved safety and efficacy compared to animal-derived collagen
- Strategic partnerships with leading healthcare companies
- Strong IP protection
- Experienced management team
Weaknesses
- Limited commercialized products
- Reliance on partnerships for product development and commercialization
- Limited financial resources compared to larger competitors
- Regulatory hurdles and long development timelines
Opportunities
- Expansion into new therapeutic areas and geographic markets
- Increased adoption of rhCollagen in regenerative medicine applications
- Advancements in bioprinting technology
- Potential for strategic acquisitions or licensing deals
- Growing market for aesthetic procedures
Threats
- Competition from established players in regenerative medicine and aesthetic medicine
- Regulatory setbacks
- Clinical trial failures
- Technological disruptions
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- MDT
- SYK
Competitive Landscape
Collplant's advantage lies in its rhCollagen technology, offering a unique alternative to animal-derived collagen. However, it faces significant competition from larger companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the development of the products and the associated approval / commercialization path.
Future Projections: Future projections depend on clinical trial success and market adoption of Vergenix STR and other products. These can vary widely based on analyst estimates.
Recent Initiatives: Recent initiatives include pursuing further clinical trials for their products, strategic partnerships for expanded applications of their technology, and ongoing research and development of new rhCollagen-based products.
Summary
Collplant Biotechnologies is an innovative company with a proprietary rhCollagen platform. Its strengths include a novel technology and strategic partnerships. The company faces challenges due to limited commercialized products and reliance on partners. Future success depends on the success of clinical trials and adoption of its products in the regenerative medicine market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Actual market share may vary. Financial data is based on publicly available information, and its accuracy cannot be guaranteed. This analysis is subject to change based on new information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://collplant.com |
Full time employees 57 | Website https://collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.